Verona Pharma to Report First Quarter 2025 Financial Results: Corporate Update and Conference Call

Verona Pharma plc is set to announce its financial results for the first quarter of 2025 on April 29, 2025. This report will include a corporate update and an invitation to join a conference call for investors and the financial community. Discover the details below!

Key Announcement Details

Financial Results Release

• Date: Tuesday, April 29, 2025
• Time:
  • 9:00 a.m. EDT
  • 2:00 p.m. BST

Conference Call Information

• Dial-in Numbers:
  • U.S. Callers: +1-800-715-9871
  • International Callers: +1-646-307-1963
• Webcast: A live webcast will be available on the Events and Presentations link on the Investors page of Verona Pharma's website.
• Audio Replay: Available for 90 days post-call.

About Verona Pharma

Verona Pharma is a biopharmaceutical company dedicated to developing innovative therapies for chronic respiratory diseases. The company focuses on addressing significant unmet medical needs through its lead product, Ohtuvayre™ (ensifentrine).

Ohtuvayre™ (Ensifentrine)

• Type: First inhaled therapy for chronic obstructive pulmonary disease (COPD)
• Mechanism: Combines bronchodilator and non-steroidal anti-inflammatory properties in one molecule
• Potential Applications:
  • Non-cystic fibrosis bronchiectasis
  • Cystic fibrosis
  • Asthma
  • Other respiratory diseases

For further information about Verona Pharma and its products, please visit their official website.

Conclusion

Verona Pharma's upcoming financial results and corporate update present an opportunity for investors and interested parties to gain insights into the company's progress and future directions. Be sure to tune in to the conference call or access the webcast for the latest updates.

Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always do your own research or consult a licensed financial advisor before making investment decisions.